<- Back to digest

JOA - 2026-11-05 - Journal Article

2025 International Consensus Meeting Definition of Success for Treatment of Periprosthetic Joint Infection.

Tarabichi S, Verhey JT, Bhandari M, Diaz-Ledezma C, Vaznaisiene D, Bingham JS, Mont MM, Spangehl MJ, Parvizi J

surveyLOE Vn = N/AN/A

Topics

arthroplasty
PMID: 42988286DOI: 10.1016/j.arth.2026.10.049View on PubMed ->

Key Takeaway

The 2025 ICM defines PJI treatment success as absence of clinical failure post-reimplantation, no PJI-attributable reoperation, no suppressive antibiotics beyond 1 year, and no PJI-related mortality—addressing a gap that produced reported success rates ranging from 54.2% to 88.9% across the literature.

Summary Depth

Choose how much analysis to show on this article page.

Summary

Prior PJI outcome definitions lacked standardization, producing success rate variability of 54.2–88.9% across studies. A multidisciplinary international workgroup convened at the 2025 ICM to establish a consensus definition of treatment success. The resulting definition requires four simultaneous criteria: no clinical failure after reimplantation, no PJI-attributable revision or reoperation, no suppressive antibiotics beyond 1 year from surgical intervention, and no PJI-related mortality, with outcome assessment beginning at the index surgical procedure.

Key Limitation

The definition has not been prospectively validated in a clinical cohort, so its sensitivity and specificity for capturing true treatment failure versus microbiologic persistence remain unknown.

Original Abstract

Periprosthetic joint infection (PJI) remains one of the most devastating complications following total joint arthroplasty (TJA). Nevertheless, a universally accepted definition of treatment success and failure has not been described to date. Current definitions each carry major limitations that fail to account for the full spectrum of clinical scenarios encountered in practice and do not adequately reflect the evolving understanding of PJI pathogenesis. Consequently, reported treatment success rates vary widely across the literature, ranging from 54.2 to 88.9%. The purpose of this initiative was to engage the orthopaedic and infectious disease communities to establish a revised, practical, and consensus-driven definition for PJI treatment outcomes. The 2025 International Consensus Meeting convened a multidisciplinary international workgroup, which defined treatment success as the absence of clinical failure following reimplantation, no revision surgery or reoperation attributable to PJI, no requirement for suppressive antibiotics beyond one year from surgical intervention, and no PJI-related mortality. Outcomes assessment initiates at the time of index surgical intervention, regardless of the procedure performed, and all subsequent revision arthroplasty must be adequately investigated to rule out an infectious etiology. The extent of this evaluation should include serologic markers, joint aspiration, and intraoperative cultures, in accordance with validated diagnostic criteria. It is hoped that adoption of this standardized definition will reduce reporting variability, facilitate more accurate assessment of emerging surgical interventions, and enable meaningful comparison of treatment efficacy across institutions and future studies.